MedTrace Logo

A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure

NCT01241396 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2396

Last updated 2016-06-20

No results posted yet for this study

Summary

The primary objective of this observational study is to document and describe current treatment regimens and disease progression of patients with Multiple Myeloma (MMY). The aim of this registry is to provide accurate, descriptive information on the way Multiple Myeloma is treated in routine clinical practice. The registry will collect information related to the treatment received for Multiple Myeloma. About 3000 patients will take part in the study in about 28 countries. The registry will only collect information that is already in medical files regarding treatment. Patients will not be required to actively do anything in addition to what would be done without participating in this registry, nor will there be any procedures or interventions that are not already part of the current treatment.

Conditions

Interventions

OTHER

Any MMY treatment

Any line of treatment for MMY

Sponsors & Collaborators

  • Janssen Pharmaceutica N.V., Belgium

    lead INDUSTRY

Principal Investigators

  • Janssen Pharmaceutica N.V. Clinical Trial · Janssen Pharmaceutica N.V.

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Algeria
  • Austria
  • Croatia
  • Denmark
  • Estonia
  • France
  • Germany
  • Greece
  • Hungary
  • Israel
  • Latvia
  • Lithuania
  • North Macedonia
  • Poland
  • Portugal
  • Russia
  • Slovenia
  • South Africa
  • Spain
  • Turkey (Türkiye)
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01241396 on ClinicalTrials.gov